MyMD Pharmaceuticals, Inc.

( )
AKER After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -1.49%176.120.7%$1154.91m
LLYEli Lilly & Co. -0.17%368.681.1%$1075.50m
MRKMerck & Co., Inc. -0.98%108.930.7%$992.38m
PFEPfizer Inc. -2.01%49.710.9%$934.38m
ABBVAbbVie, Inc. -0.11%163.761.9%$884.04m
BMYBristol-Myers Squibb Co. -0.98%79.911.1%$741.36m
AZNAstraZeneca Plc 0.21%68.561.0%$355.43m
HZNPHorizon Therapeutics Plc -1.66%96.855.4%$295.13m
GSKGSK Plc 7.85%37.920.3%$247.06m
IDXXIDEXX Laboratories, Inc. -1.64%415.393.9%$191.92m
NVSNovartis AG -0.25%90.730.2%$185.59m
CTLTCatalent, Inc. -5.00%48.231.9%$175.42m
ALNYAlnylam Pharmaceuticals, Inc. -2.90%219.648.0%$156.22m
NVONovo Nordisk A/S -1.03%125.770.1%$154.68m
SNYSanofi 8.06%48.550.2%$133.18m

Company Profile

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.